Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Paratek Pharmaceuticals, Inc.

http://paratekpharma.com/

Latest From Paratek Pharmaceuticals, Inc.

RNA Medicines: Advancements Leading To Investments

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Outlook 2023 Growth

The Busiest Dealmakers Of 2022

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Outlook 2023 M & A

US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

Clinical Trials Guidance Documents

Trials In Focus: FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.

Clinical Trials Guidance Documents
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Novacea, Inc.
    • Transcept Pharmaceuticals, Inc.
    • TransOral Pharmaceuticals, Inc.
UsernamePublicRestriction

Register